Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX Other stock markets 11:26:01 29/04/2024 pm IST			5-day change	1st Jan Change
66.4 ^USD	+1.50%		-0.69%	-17.93%

02:31pm	Barclays Adjusts Price Target on Gilead Sciences to $76 From $80	MT
26/04	TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Adjusts Price Target on Gilead Sciences to $76 From $80	06:01pm	MT
TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90	26/04	MT
Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95	26/04	MT
RBC Capital Adjusts Gilead Sciences' Price Target to $74 From $76	26/04	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $78 From $80	26/04	MT
North American Morning Briefing : More Tech -2-	25/04	DJ
HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69	24/04	MT
Argus Cuts Price Target on Gilead Sciences to $75 From $85	23/04	MT
Cantor Fitzgerald Adjusts Gilead Sciences' Price Target to $75 From $78, Maintains Neutral Rating	22/04	MT
BMO Capital Adjusts Price Target on Gilead Sciences to $80 From $89	19/04	MT
Leerink Partners Adjusts Gilead Sciences Price Target to $74 From $79	19/04	MT
UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating	17/04	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76	15/04	MT
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating	09/04	MT
Wells Fargo Cuts Price Target on Gilead Sciences to $78 From $84, Keeps Equalweight Rating	04/03	MT
Mizuho Securities Cuts Price Target on Gilead Sciences to $90 From $101, Maintains Buy Rating	22/02	MT
Truist Securities Downgrades Gilead Sciences to Hold From Buy, Cuts Price Target to $82 From $91	22/02	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	16/02
RBC Trims Price Target on Gilead Sciences to $75 From $76, Keeps Sector Perform Rating	14/02	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	13/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Gilead Sciences, Inc.

Equities

GILD

US3755581036

Analyst Reco.

Filters